The Cannabis Risk That Quietly Died in January: What It Means for $MSOS, $TLRY, $CGC and $ACB

A room with about twenty-five chairs

The building at 700 Army Navy Drive in Arlington, Virginia does not look like the place where a multi-billion-dollar industry gets rearranged. On June 29, 2026, roughly twenty-five members of the public sat in the DEA’s hearing facility to watch the opening of the formal proceeding on moving marijuana from Schedule I to Schedule III of the Controlled Substances Act.

Twenty-five. Not twenty-five thousand watching a stream, not a televised committee hearing with lawmakers performing for cameras. The DEA’s standing order was explicit: the proceeding would not be televised, livestreamed or broadcast in any way. Members of the public could attend in person, the agency said, because of the “national public interest in this issue” — which is a striking phrase to attach to a room with limited seating and no cameras.

The hearing ran from June 29 to July 15, with a recess from July 3 to July 6 for Independence Day. It had an unusual structure that we covered at the time: the designated participants selected to testify were the parties opposed to rescheduling. The government’s case was built through cross-examination of those opponents rather than through a parade of friendly witnesses. The DEA’s lead counsel put the central question on the table in the opening minutes — whether marijuana has a currently accepted medical use, because if it does, Schedule I becomes legally untenable.

That is where the attention went. Traders followed the daily reports, waited for July 15, and treated it as the date when something would resolve. It was not. And while everyone was looking at Arlington, the more consequential thing had already happened six months earlier, four miles away, in the Capitol.

The provision nobody wrote about

Go back to September 2025. The House Appropriations Committee approved its Fiscal Year 2026 Commerce, Justice, Science and Related Agencies bill by a vote of 34 to 28. Buried in the text was language prohibiting the Department of Justice from spending any funds to reschedule marijuana or to remove it from the schedules established under the Controlled Substances Act.

Read that again, because the mechanism matters. That provision would not have argued about medical use. It would not have contested potency data or driving studies or the CAMU test. It would simply have removed the money. A federal agency that cannot spend funds on an action cannot take the action, no matter what an administrative law judge recommends or what an administrator decides. It was, in practical terms, a kill switch sitting outside the entire proceeding.

Then it vanished. The bicameral agreement unveiled on January 5, 2026 omitted the blocking language entirely. On January 9, the House passed the final bill by 397 to 28. What survived instead was the long-standing rider — renewed annually since 2014 — that bars the Justice Department from interfering with state medical marijuana laws.

A 397-28 vote is not a narrow escape. It is a chamber that had stopped fighting about this.

What changed between September and January

The political weather. In December 2025, President Trump signed an executive order directing the Attorney General’s office to expedite rescheduling of medical marijuana to Schedule III. In April 2026, Acting Attorney General Todd Blanche issued the order that immediately placed FDA-approved marijuana products and state-licensed medical marijuana products into Schedule III, and simultaneously set the expedited hearing process for the broader question.

Once the administration owned the policy, maintaining a Republican-authored provision designed to stop that same administration became politically awkward. Representative Byron Donalds of Florida put it plainly when asked about efforts to block rescheduling: “I don’t see how they’re going to get it through.”

Trump, for his part, framed the move in the language he uses for things he considers settled: common sense, and a claim that 82% of Americans support it. Whether that number is right is a separate question. What matters for the risk analysis is that when a president adopts a position, the appropriations knife aimed at that position tends to get put away.

Meanwhile, the tape

Here is where the story turns uncomfortable for anyone who assumed policy progress translates into price.

Look at the shape rather than the numbers. Every name ticked up into the June 29 opening — the small bid of anticipation. Then each one drifted lower for two and a half weeks while the hearing produced testimony. And on July 15, the day the proceeding closed, there was no spike, no capitulation, no volume event. Nothing.

The sector fell during the very period when its central regulatory case was being argued and, on the record, largely surviving.

Why a good process produced a bad tape

Because the market was not trading the process. It was trading a date that did not exist.

A great deal of retail positioning in cannabis this spring was built on the idea that July 15 was a decision day. It never was. July 15 was the last day of evidentiary testimony — the end of the record-building phase, not the beginning of an answer. When that day arrived and delivered exactly what the docket said it would deliver, which is to say nothing resolved, the positions built around a phantom catalyst had no reason to stay.

There is a second, less comfortable reading. The removal of the appropriations threat happened in January, quietly, in a spending bill most cannabis investors never opened. If that risk was never priced in the first place — if the market simply did not know it was carrying it — then removing it produced no rally, because there was no discount to unwind. Good news that nobody knew was at stake is not good news at all, at least not to a price chart.

Where the record actually landed

We covered this in detail in our final hearing wrap, so briefly: the government’s core theory came through intact but bruised. Opponents built a serious, appeal-ready record around botanical variability, the mismatch between research-grade cannabis and high-potency retail products, impaired driving and the legal standard for accepted medical use.

The most quoted moment came from the other side of the table. Harvard psychobiology professor Bertha Madras, a prominent opponent, reportedly acknowledged under government cross-examination that marijuana meets the statutory criteria associated with Schedule III, and that it does not cause the respiratory-depression deaths associated with opioids because cannabinoid receptors do not regulate breathing the same way.

We flagged the caveat then and we flag it again now: the corrected official transcript still has not been published. That exchange should be treated as a corroborated courtroom report, not as a verified quotation. If it holds up in the final record, it will be one of the strongest passages the government has. If the wording turns out to be more qualified than reported, it will be one of the more embarrassing episodes of this news cycle.

The opposition is already building the appeal

Kevin Sabet, who runs Smart Approaches to Marijuana, has argued that this rescheduling is “solely political,” pointing at campaign donations. It would be easy to file that under noise, except for one detail: SAM is one of the seven designated parties in the proceeding. That is not an outside pundit throwing rocks — it is a participant with standing, shaping a narrative that maps neatly onto a future administrative-procedure challenge.

The full list of designated parties, confirmed on the DEA’s own page, is worth keeping: the National Drug & Alcohol Screening Association, the Tennessee Bureau of Investigation, Smart Approaches to Marijuana, the States of Nebraska, Idaho, Indiana and Louisiana, DUID Victim Voices, Kenneth Finn MD, and Phillip A. Drum PharmD. Four state governments are in that list. Any final Schedule III rule will be born into a ready-made pool of litigants.

What happens now: paper, and silence

We checked the DEA’s public pages on July 19. There is no recommended decision, no final rule and no official transcript. The agency’s administrative law judge orders page contains only filings from 2024 — that is, from the earlier proceeding that was withdrawn. Of the current hearing, not a single order has been posted publicly.

Trade press has reported that Chief Administrative Law Judge Derek Julius set August 17, 2026 as the deadline for optional post-hearing briefs. We could not confirm that date on DEA.gov, in the judge’s orders, or in the Federal Register, so we are reporting it as a press account rather than a verified schedule. If it is accurate, it is the next real marker on the calendar.

After the briefs, Judge Julius writes a recommended decision. It is not binding. It goes to DEA Administrator Terry Cole, who makes the agency’s final call. Then, in all likelihood, the litigation begins.

There have been no leaks. No anticipated rulings, no sourced reports about which way the recommendation is leaning, no political comment of substance since July 15. For a story this large that silence is itself informative: the phase we are in is written, private and slow, and it will stay that way until a document appears.

Bottom line

The cannabis trade spent the spring watching the wrong room. The most decisive event of 2026 for federal rescheduling was not a cross-examination in Arlington — it was a provision removed from a spending bill in January and a 397-28 vote that almost no cannabis investor registered. The kill switch is gone.

What remains is slower and less dramatic: a written phase with no public filings, an unconfirmed August brief deadline, a non-binding recommendation, an administrator’s decision, and a queue of well-prepared opponents including four state governments. Meanwhile the tape fell 2% to 9% across the major proxies during the hearing itself, because the market had positioned for a verdict day that the docket never promised.

The honest framing is not “rescheduling is winning” and not “the trade is dead.” It is that the structural risk profile improved materially in January without anyone noticing, the evidentiary record came through damaged but alive in July, and the next genuine catalyst is a document that does not yet have a publication date. Positioning around an administrative proceeding requires patience with paper, not a countdown clock.